JP2018515605A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515605A5 JP2018515605A5 JP2018510322A JP2018510322A JP2018515605A5 JP 2018515605 A5 JP2018515605 A5 JP 2018515605A5 JP 2018510322 A JP2018510322 A JP 2018510322A JP 2018510322 A JP2018510322 A JP 2018510322A JP 2018515605 A5 JP2018515605 A5 JP 2018515605A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- composition
- subject
- ldl
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158157P | 2015-05-07 | 2015-05-07 | |
| US62/158,157 | 2015-05-07 | ||
| PCT/US2016/031109 WO2016179456A1 (en) | 2015-05-07 | 2016-05-06 | Use of cd24 for lowering low-density lipoprotein cholesterol levels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515605A JP2018515605A (ja) | 2018-06-14 |
| JP2018515605A5 true JP2018515605A5 (https=) | 2019-04-11 |
| JP6751756B2 JP6751756B2 (ja) | 2020-09-09 |
Family
ID=57218627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510322A Expired - Fee Related JP6751756B2 (ja) | 2015-05-07 | 2016-05-06 | 低密度リポタンパク質コレステロールレベルを低下させるためのｃｄ２４の使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10369197B2 (https=) |
| EP (1) | EP3292144B1 (https=) |
| JP (1) | JP6751756B2 (https=) |
| KR (1) | KR20170141216A (https=) |
| CN (1) | CN107531772B (https=) |
| AU (1) | AU2016258084B2 (https=) |
| BR (1) | BR112017022394A2 (https=) |
| CA (1) | CA2982612A1 (https=) |
| EA (1) | EA038520B1 (https=) |
| ES (1) | ES2829235T3 (https=) |
| HK (1) | HK1249521A1 (https=) |
| HR (1) | HRP20201651T1 (https=) |
| HU (1) | HUE051866T2 (https=) |
| IL (1) | IL255086B (https=) |
| MX (1) | MX385941B (https=) |
| PT (1) | PT3292144T (https=) |
| WO (1) | WO2016179456A1 (https=) |
| ZA (1) | ZA201706846B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20201651T1 (hr) * | 2015-05-07 | 2020-12-25 | Oncoimmune, Inc. | Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola |
| JP2020510020A (ja) * | 2017-03-07 | 2020-04-02 | オンコイミューン， インコーポレイテッド | 全身性エリテマトーデスを治療するために可溶性ｃｄ２４を使用する方法 |
| WO2019113123A1 (en) * | 2017-12-04 | 2019-06-13 | Precithera, Inc. | TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING |
| CN112543643A (zh) * | 2018-03-05 | 2021-03-23 | 肿瘤免疫股份有限公司 | 使用可溶性cd24用于治疗获得性免疫缺陷综合征（hiv/aids）的方法 |
| MA52811A (fr) * | 2018-06-04 | 2022-03-16 | Oncoimmune Inc | Procédés d'utilisation de cd24 pour la prévention et le traitement d'une rechute de la leucémie |
| WO2020084034A1 (en) | 2018-10-26 | 2020-04-30 | F. Hoffmann-La Roche Ag | Multispecific antibody screening method using recombinase mediated cassette exchange |
| CA3128503A1 (en) * | 2019-02-06 | 2020-08-13 | Oncoimmune, Inc. | Targeting cd24-siglec interactions for treating subjects with prediabetes or diabetes |
| US20220000973A1 (en) * | 2019-02-06 | 2022-01-06 | Oncolmmune, Inc. | Targeting CD24-Siglec Interactions for the Treatment and Prevention of Nonalcoholic Steatohepatitis |
| WO2021160170A1 (en) * | 2020-02-10 | 2021-08-19 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating sars-cov-2 infection |
| EP4103217A4 (en) * | 2020-02-10 | 2024-03-13 | Oncoimmune Inc. | METHOD OF USING SOLUBLE CD24 TO TREAT VIRAL PNEUMONIA |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544566B1 (en) * | 1999-04-23 | 2003-04-08 | Protein Technologies International, Inc. | Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol |
| AU2001259792B2 (en) * | 2000-03-29 | 2005-12-22 | The Ohio State University Research Foundation | Methods of blocking tissue destruction by autoreactive T cells |
| CN1981772A (zh) * | 2000-05-13 | 2007-06-20 | 阿彻-丹尼尔斯-米德兰公司 | 降低低密度脂蛋白胆固醇浓度的组合物和方法 |
| WO2009086284A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neaural and glial tumors of the brain |
| US8163281B2 (en) * | 2009-03-04 | 2012-04-24 | The Regents Of The University Of Michigan | Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis |
| US8354520B2 (en) * | 2009-12-10 | 2013-01-15 | Kaohsiung Medical University | Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug |
| US20130231464A1 (en) * | 2010-04-28 | 2013-09-05 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
| US8808697B2 (en) * | 2010-04-28 | 2014-08-19 | Oncoimmune, Inc. | Methods of use of soluble CD24 for therapy of rheumatoid arthritis |
| AU2012267489B2 (en) * | 2011-06-10 | 2017-03-16 | The Trustees Of The University Of Pennsylvania | System and method of cytomic vascular health profiling |
| HRP20201651T1 (hr) * | 2015-05-07 | 2020-12-25 | Oncoimmune, Inc. | Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola |
-
2016
- 2016-05-06 HR HRP20201651TT patent/HRP20201651T1/hr unknown
- 2016-05-06 JP JP2018510322A patent/JP6751756B2/ja not_active Expired - Fee Related
- 2016-05-06 HU HUE16790128A patent/HUE051866T2/hu unknown
- 2016-05-06 EA EA201792418A patent/EA038520B1/ru unknown
- 2016-05-06 BR BR112017022394A patent/BR112017022394A2/pt not_active IP Right Cessation
- 2016-05-06 HK HK18107984.3A patent/HK1249521A1/zh unknown
- 2016-05-06 ES ES16790128T patent/ES2829235T3/es active Active
- 2016-05-06 WO PCT/US2016/031109 patent/WO2016179456A1/en not_active Ceased
- 2016-05-06 EP EP16790128.9A patent/EP3292144B1/en active Active
- 2016-05-06 CA CA2982612A patent/CA2982612A1/en not_active Abandoned
- 2016-05-06 CN CN201680026449.2A patent/CN107531772B/zh not_active Expired - Fee Related
- 2016-05-06 MX MX2017014095A patent/MX385941B/es unknown
- 2016-05-06 AU AU2016258084A patent/AU2016258084B2/en not_active Ceased
- 2016-05-06 PT PT167901289T patent/PT3292144T/pt unknown
- 2016-05-06 KR KR1020177032235A patent/KR20170141216A/ko not_active Ceased
- 2016-05-06 US US15/572,330 patent/US10369197B2/en not_active Expired - Fee Related
-
2017
- 2017-10-10 ZA ZA2017/06846A patent/ZA201706846B/en unknown
- 2017-10-17 IL IL255086A patent/IL255086B/en unknown
-
2019
- 2019-06-17 US US16/443,498 patent/US11026995B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515605A5 (https=) | ||
| JP7166478B2 (ja) | ヒトヒアルロニダーゼｐｈ２０の変異体及び薬物を含む皮下投与用医薬組成物 | |
| Lei et al. | Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig | |
| Deng et al. | Nav1. 7 is essential for nociceptor action potentials in the mouse in a manner independent of endogenous opioids | |
| Markusic et al. | Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies | |
| Pipe et al. | Hemophilia A gene therapy: current and next-generation approaches | |
| Chowdary | Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab: P. Chowdary | |
| Veritti et al. | Neovascular age-related macular degeneration | |
| Schellekens | Factors influencing the immunogenicity of therapeutic proteins | |
| Whiteaker et al. | Discovery, synthesis, and structure activity of a highly selective α7 nicotinic acetylcholine receptor antagonist | |
| US7303748B2 (en) | Method of treating eye injury with local administration of a VEGF inhibitor | |
| Palmer et al. | Liddle’s syndrome | |
| JP2013527168A5 (https=) | ||
| EA029215B1 (ru) | Стабильные водные составы адалимумаба | |
| Carr et al. | Emerging and future therapies for hemophilia | |
| Morar-Mitrica et al. | Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration | |
| Klinge et al. | Hemophilia A-from basic science to clinical practice | |
| CN107531772A (zh) | Cd24用于降低低密度脂蛋白胆固醇水平的用途 | |
| Hermans et al. | Recombinant factor VIII Fc for the treatment of haemophilia A | |
| Sun et al. | Gene delivery of activated factor VII using alternative adeno-associated virus serotype improves hemostasis in hemophiliac mice with FVIII inhibitors and adeno-associated virus neutralizing antibodies | |
| JP2016530284A (ja) | 疾患及び障害を治療するためにインターロイキン−１０を使用する方法 | |
| Miesbach et al. | Liver-related aspects of gene therapy for haemophilia: call to action for collaboration between haematologists and hepatologists | |
| Valentino et al. | The biological efficacy profile of BAX 855, a PEG ylated recombinant factor VIII molecule | |
| Jiang et al. | 2025 clinical trials update on hemophilia, VWD, and rare inherited bleeding disorders | |
| Akbayir et al. | Is there any relationship between hepatitis C virus and vitiligo? |